We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alzheimer's Disease Biomarker Assay Heading for IVD Status

By LabMedica International staff writers
Posted on 24 Jul 2017
A clinical diagnostic kit that measures the concentration of the Alzheimer's disease blood biomarker APOEepsilon4 was unveiled at the Alzheimer’s Association Conference held in London, United Kingdom, from July 16-20, 2017.

The risk of developing Alzheimer’s disease (AD) is increased by three to five-folds with the presence of one epsilon4 allele and between 15 and 20 times with two alleles.

The frequency of the epsilon4 allele is approximately 40% in patients with AD. More...
Furthermore, APOEepsilon4 carriers progress faster to clinical AD than do APOEepsilon4 non-carriers. Therefore, the presence of one or two epsilon4 alleles of the APOE gene is considered to be highly informative in epidemiological research and is currently being used for patient stratification in the latest clinical trials to evaluate AD treatments.

The Biocross (Valladolid, Spain) ApoE4 Blood Marker Assay is an immunoturbidimetry-based test. Each assay kit consists of two reagents: R1 (which contains a highly specific anti-apoE4 antibody) and R2 (a solution containing latex (polystyrene beads). During the assay, the anti-apoE4 antibody induces the agglutination of latex beads in the presence of apoE4 in the sample. This agglutination is proportional to the concentration of the apoE4 and can be measured manually or automatically with a spectrophotometer.

The ApoE4 Blood Marker Assay can be used with manageable cost in any of the clinical biochemistry analyzers that are available in most hospitals or clinical centers. The risk indicator is determined by a cost-effective and accurate blood test that is scheduled to obtain the European IVD CE mark and will be submitted for [U.S.] Food and Drug Administration approval by the end of the year.

Matthew Mittino, CEO of Biocross, said, “Introducing our risk test ApoE4 Blood Marker Assay to experts, researchers, physicians, neurologists, and specialists in neurodegenerative diseases from more than 70 countries, will mark a before and an after within clinical practice. It is a risk indicator that is already a qualitative leap, a cost-effective alternative in front of the existing ones. Now, the next step is to carry out an important information work to show its advantages to all professionals of the industry and to make it useful for improving people life quality.”

Related Links:
Biocross


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.